Comparison of bronchodilatation produced by an anticholinergic (ipratropium bromide), a beta-2 adrenergic (fenoterol) and their combination in patients with chronic obstructive airway disease. An open trial.

Simple item page
dc.contributor.authorGuleria, Ren_US
dc.contributor.authorBehera, Den_US
dc.contributor.authorJindal, S Ken_US
dc.date.accessioned1991-09-01en_US
dc.date.accessioned2009-05-31T05:16:34Z
dc.date.available1991-09-01en_US
dc.date.available2009-05-31T05:16:34Z
dc.date.issued1991-09-01en_US
dc.description.abstractFenoterol hydrobromide (200 micrograms), ipratropium bromide (40 micrograms) and a combination of the two in the same dosage were administered by metered dose inhaler on 3 separate days to 20 patients with chronic bronchitis and emphysema. On each day, baseline forced vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow rate (PEFR) and mid maximum flow rate (MMFR) were recorded. The values were again recorded after administration of the drug at 15, 30, 45 and 60 minutes. Side effects if any were recorded. There was a significant increase from baseline in FVC and FEV1 with all the three regimens at 15, 30 and 45 minutes. However, the rise in MMFR was significant only with ipratropium bromide and the combination regimen. At 60 minutes, the rise in FVC, FEV1 and MMFR was significant only with the combination regimen. There was no significant change in the PEFR values at any time with any drug. The difference in rise in all the four parameters with the 3 regimens was not statistically significant. No side effects were noted. Thus, a combination fenoterol and ipratropium bromide produced a more prolonged bronchodilatation, and ipratropium bromide perhaps acts both in the major (indicated by rise in FEV1) and small airways (measured by MMFR).en_US
dc.description.affiliationDepartment of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research.en_US
dc.identifier.citationGuleria R, Behera D, Jindal SK. Comparison of bronchodilatation produced by an anticholinergic (ipratropium bromide), a beta-2 adrenergic (fenoterol) and their combination in patients with chronic obstructive airway disease. An open trial. Journal of the Association of Physicians of India. 1991 Sep; 39(9): 680-2en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/95443
dc.language.isoengen_US
dc.source.urihttps://www.japi.orgen_US
dc.subject.meshAerosolsen_US
dc.subject.meshBronchi --drug effectsen_US
dc.subject.meshBronchitis --drug therapyen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFenoterol --therapeutic useen_US
dc.subject.meshHumansen_US
dc.subject.meshIpratropium --therapeutic useen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPulmonary Emphysema --drug therapyen_US
dc.titleComparison of bronchodilatation produced by an anticholinergic (ipratropium bromide), a beta-2 adrenergic (fenoterol) and their combination in patients with chronic obstructive airway disease. An open trial.en_US
dc.typeClinical Trialen_US
dc.typeComparative Studyen_US
dc.typeControlled Clinical Trialen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Association of Physicians of India